Showing 5571-5580 of 10571 results for "".
- Merz Makes Offer for Obagihttps://practicaldermatology.com/news/20130402-merz_makes_offer_for_obagi/2459576/With an unexpected $383.5 million bid, Merz Pharma Group formally proposed to acquire Obagi Medical Products, outdoing rival Valeant's bid for Obagi announced late last month and reported in yesterday's edition of DermWire. Merz sent a letter to Obagi Medical Products Inc.'s board offering to buy al
- Veil Cosmetics Introduced to Markethttps://practicaldermatology.com/news/20120727-veil_cosmetics_introduced_to_market/2459761/The concept of makeup artist Sébastien Tardif, Veil Cosmetics was inspired by Tardif's foundation in both art and fashion, which inspired the palette of bright-based colors that lift and illuminate the skin. Tardif cultivated his skincare sensibilities during his tenure in Asia, which led him
- Reduced AMP Expression Seen in Sensitive Skin Syndrome: Pilot Studyhttps://practicaldermatology.com/news/reduced-amp-expression-seen-in-sensitive-skin-syndrome-pilot-study/2486974/A pilot study published in the Journal of the American Academy of Dermatology evaluated whether key pathophysiologic features of rosacea—Demodex colonization and antimicrobial peptide (AMP) dysregulation—are also present in
- Rapid Weight Loss Brings Expanding Soft Tissue Concerns to Dermatologyhttps://practicaldermatology.com/news/rapid-weight-loss-brings-expanding-soft-tissue-concerns-to-dermatology/2486936/A new analysis suggests rapid weight loss from GLP-1 agents, bariatric surgery, or lifestyle change is associated with measurable declines in skin elasticity and soft tissue volume.Rapid and intentional weight loss (driven by bariatric surgery, glucagon-l
- Study Highlights Demographic Factors Linked to Variability in Skin Barrier Functionhttps://practicaldermatology.com/news/study-highlights-demographic-factors-linked-to-variability-in-skin-barrier-function/2486935/Older age, female sex, Black race, and higher BMI were each associated with at least one measure of improved skin barrier function, according to new results published in JID Innovations. Investigators for the cross-sectional analysis of 286 participants fro
- Exosomes in Dermatology: Emerging Adjuncts With Uncertain Standardizationhttps://practicaldermatology.com/news/exosomes-in-dermatology-emerging-adjuncts-with-uncertain-standardization/2486899/A recent narrative synthesized evidence from 2020 to 2025 on exosome-based therapeutics, highlighting their expanding role in dermatology and regenerative medicine. Across dermatologic applications, the authors wrote, precli
- Dr. Miriam Bettencourt Speaks on Measles Resurgence and the Dermatologist’s Rolehttps://practicaldermatology.com/news/dr-miriam-bettencourt-speaks-on-measles-resurgence-and-the-dermatologists-role/2486877/As the ominous music from the “Mission Impossible” movies played over the speakers, a dramatic voice spoke: “Good morning, doctors. Sixty years of safe and effective vaccine has resulted in the eradication of measles. Recently, however, a distrust of science has pr
- Incyte Reports Positive Vitiligo Phase 3 Data Supporting JAK Therapieshttps://practicaldermatology.com/news/incyte-reports-positive-vitiligo-phase-3-data-supporting-jak-pipeline/2486888/Incyte provided updated data on two therapies in its dermatology pipeline during its recent earnings call, according to a statement from the company. Ruxolitinib Update
- FDA Flags Six Additional Gel Nail Removers for Banned Chemicalhttps://practicaldermatology.com/news/fda-flags-six-additional-gel-nail-removers-for-banned-chemical/2486820/The US Food and Drug Administration (FDA) has identified six additional cosmetic products marketed as gel nail polish removers that contain methylene chloride, a substance prohibited for use in cosmetics, according to a statement from the agency.</
- AAD Pediatric Guidelines Give Strong Backing to Roflumilast Creamhttps://practicaldermatology.com/news/aad-pediatric-guidelines-give-strong-backing-to-roflumilast-cream/2486794/Arcutis Biotherapeutics announced that ZORYVE (roflumilast) cream has received a strong recommendation in the American Academy of Dermatology (AAD) clinical practice guidelines for pediatric atopic dermatitis (AD), marking inclusion in the organization’s first guid